Detection of a PDGFRB fusion in refractory CMML without eosinophilia: A case for broad spectrum tumor profiling

Gillian C. Bell a, b, Eric Padron c, *

a DeBartolo Family Personalized Medicine Institute, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, United States
b Department of Population Sciences, H. Lee Moffitt Cancer and Research Institute, Tampa, FL, United States
c Department of Hematologic Malignancies and Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States

A R T I C L E  I N F O
Article history:
Received 13 April 2015
Received in revised form 30 June 2015
Accepted 23 July 2015
Available online 24 September 2015

A B S T R A C T
In this case report, we describe a refractory CMML case without eosinophilia harboring a PDGFRB rearrangement leading to a favorable response with imatinib. We believe this case demonstrates the utility of broad spectrum genomic profiling in refractory CMML cases as an opportunity to uncover additional treatment options.

Chronic Myelomonocytic Leukemia (CMML) with eosinophilia has been historically associated with rearrangements of PDGFRB or \( \beta [1,2] \). Although this entity has now been reclassified as distinct from CMML by the World Health Organization (WHO) [3], clinicians reserve routine evaluation of PDGFR rearrangements in suspected CMML cases with eosinophilia because this genetic lesion predicts response to imatinib. A recent article by Cheah et al. report durable long-term remissions with the use of imatinib in a collection of patients with myeloid malignancies bearing PDGFRB fusions [4]. They confirm that the formation of PDGFRB fusion genes secondary to rearrangement of PDGFR at 5q31-33 constitutively activates the PDGFRB receptor tyrosine kinase and are exquisitely sensitive to treatment with imatinib [1,5] All patients in this report had eosinophilia at diagnosis which likely triggered the evaluation for a possible PDGFRB fusion. Given the limited armamentarium available for CMML, we perform broad spectrum genomic profiling to include analysis of PDGFRB in those cases that have failed standard therapies and have no clinical trial options.

Using this strategy, we report a refractory CMML case for which a novel PDGFRB fusion was identified by next generation sequencing in a refractory CMML case without eosinophilia that achieved a favorable response with imatinib.

A 77-year-old woman was referred to our medical center for second opinion for refractory CMML-2. She had been incidentally found to have mild leukocytosis, anemia, and thrombocytosis on routine laboratory analysis. At diagnosis her white blood cell count (WBC) was \( 12 \times 10^9/L \), hemoglobin was 10.8 g/dL, and platelet count was \( 420 \times 10^9/L \). Monocytes and eosinophils constituted 19% and 1% of total WBC, respectively. Bone marrow biopsy demonstrated hypercellularity, bone marrow dysplasia, and 14% blasts consistent with a diagnosis of CMML-2. Cytogenetics were 46,XX, del(7)(q22q32) and no other analysis to interrogate PDGFR rearrangements was performed at that time.

After two cycles of 5-azacitidine, the patient proceeded to undergo matched unrelated donor allogeneic hematopoietic stem cell transplantation but subsequently had graft failure and relapsed in a CMML-2 state. Post-transplant therapies included 5-azacitidine, induction chemotherapy, and decitabine for which she did not respond. Broad spectrum molecular profiling was performed using the clinically available FoundationOne Heme assay which analyzes the complete coding DNA sequences of 405 genes, selected introns of 31 genes involved in rearrangements, and the RNA sequence of 265 commonly rearranged genes to identify gene fusions. Findings included mutations in NRAS, RUNX1, ASXL1, IKZF1, and a SDPR-PDGFRB rearrangement. SDPR is a gene that encodes a phospholipid-binding protein that has not been previously reported to partner with PDGFRB [4,6]. Given that SDPR is highly expressed in hematopoietic early progenitor cells (Fig. 1) [7,8], we hypothesized that the fusion of the SDPR promoter to the PDGFRB coding region would result in overexpression of PDGFRB as has been reported with other fusions. Her peripheral eosinophil count at the time of molecular profiling was 1.12 k/L and bone marrow biopsy was consistent with secondary AML with 36% blasts. The patient was started on 400 mg of imatinib and achieved a significant reduction in bone marrow blasts to 5%, consistent with a partial CR. Blood counts at time consisted of white blood cell count of 3 k/\( \mu L \), platelets of 108 k/\( \mu L \), hemoglobin of 8.5 g/dL and hematocrit of 25.9%. The duration of response using imatinib was approximately 4 months prior to disease progression.

* Correspondence to: Department of Hematologic Malignancies and Immunology Program H. Lee Moffitt Cancer Center and Research Institute 12902 Magnolia Drive Tampa, FL 33612. Fax: +1 813 745 3875.
E-mail address: eric.padron@moffitt.org (E. Padron).
after which the patient transitioned to best supportive care with hydroxyurea and expired 3.5 months later. CMML remains a lethal malignancy with limited treatment options. The incidence of *PDGFRB* rearrangements in myeloproliferative neoplasms (MPNs) is low; a recent study reported only 1.8% of 556 patients evaluated [2]. While MPNs with *PDGFRB* rearrangements are phenotypically diverse, CMML with eosinophilia is a common morphologic diagnosis [2,4]. We report a case of a refractory CMML case without eosinophilia harboring a *PDGFRB* rearrangement leading to a favorable response with imatinib. This case demonstrates the utility of broad spectrum genomic profiling in refractory CMML cases as an opportunity to uncover additional treatment options.

**Contribution**

G.C.B. and E.P. wrote the letter. Both authors gave final approval of the version to be published.

**Conflict-of-interest disclosure**

The authors declare no competing financial interests.

**References**

[1] V. Havelange, J.B. Demoulin, Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia, J. Blood Med. 4 (2013) 111–121.

[2] M. Arefi, J.L. Garcia, M.J. Penarrubia, et al., Incidence and clinical characteristics of myeloproliferative neoplasms displaying a *PDGFRB* rearrangement, Eur. J. Haematol. 89 (1) (2012) 37–41.

[3] S.A. Parikh, A. Tefferi, Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management, Am. J. Hematol. 87 (6) (2012) 610–619.

[4] C.Y. Cheah, K. Burbury, J.F. Apperley, et al., Patients with myeloid malignancies bearing *PDGFRB* fusion genes achieve durable long-term remissions with imatinib, Blood 123 (23) (2014) 3574–3577.

[5] R.A. Mesa, Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders, Biol.: Targets Ther. 1 (2) (2007) 129–138.

[6] N. Savage, T.I. George, J. Gotlib, Myeloid neoplasms associated with eosinophilia and rearrangement of *PDGFR*, *PDGFRB*, and *FGFR1*: a review, Int. J. Lab. Hematol. 35 (5) (2013) 491–500.

[7] F.O. Bagger, N. Rapin, K. Theilgaard-Monch, et al., HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis, Blood 119 (26) (2012) 6394–6395.

[8] F.O. Bagger, N. Rapin, K. Theilgaard-Monch, et al., HemaExplorer: a database of mRNA expression profiles in normal and malignant hematopoiesis, Nucleic Acids Res. 41 (Database issue) (2013) D1034–D1039.